AMG 355
Alternative Names: AMG-355Latest Information Update: 28 Aug 2026
At a glance
- Originator Amgen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Aug 2026 Discontinued - Phase-I for Solid tumours (Late-stage disease) (IV)
- 04 Aug 2026 Discontinued - Phase-I for Solid tumours (Metastatic disease, Combination therapy, Late-stage disease) in Canada, Japan, Taiwan, Netherlands, Poland, USA, Australia, France, Switzerland, Spain (IV) (Amgen pipeline, August 2026)
- 04 Aug 2026 Discontinued - Phase-I for Solid tumours (Metastatic disease, Late-stage disease, Monotherapy) in Australia, France, Netherlands, South Korea, Taiwan, USA, Switzerland, Spain, Poland, Japan, Canada (IV) (Amgen pipeline, August 2026)